Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thymoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 114 Cholangiocarcinoma 24 Carcinoma, Renal Cell 19 Liver Neoplasms 12 Stomach Neoplasms 10 Biliary Tract Neoplasms 10 Thyroid Neoplasms 8 Breast Neoplasms 8 Neoplasms 7 Endometrial Neoplasms 7 Recurrence 6 Neuroendocrine Tumors 5 Neoplasm Metastasis 5 Melanoma 5 Uterine Cervical Neoplasms 4 Thyroid Carcinoma, Anaplastic 4 Thyroid Cancer, Papillary 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Liver Diseases 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Carcinoma, Adenoid Cystic 3 Brain Neoplasms 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Adenocarcinoma 3 Uveal Melanoma 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma 2

Interventions

Radiotherapy 5 Cisplatin 5 pembrolizumab 4 Cyclophosphamide 4 Thymectomy 3 Sunitinib 3 130-nm albumin-bound paclitaxel 3 selinexor 2 Pemetrexed 2 Methylprednisolone 2 Etoposide 2 Drug Therapy 2 Doxorubicin 2 Chemoradiotherapy 2 Carboplatin 2 zimberelimab 1 vorolanib 1 regorafenib 1 lenvatinib 1 epacadostat 1 envafolimab 1 bosutinib 1 amrubicin 1 Thoracic Surgery, Video-Assisted 1 TP protocol 1 Ramucirumab 1 Radiotherapy, Adjuvant 1 Radiosurgery 1 Radiofrequency Ablation 1 Radiation Dose Hypofractionation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04710628 2026-02-19

PECATI

MedSIR

Phase 2 Completed

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡